Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Telo Genomics Corp V.TELO

Alternate Symbol(s):  TDSGF

Healthcare Industrials Biotechnology Conglomerates
Telo Genomics Corp. is a biotech company pioneering the telomere platform in the industry with applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. The Company's lead application, TELO-MM is being developed to provide actionable information to medical professionals in the treatment of multiple myeloma, a form of blood cancer. Its clinical studies and product development design includes TeloView SMM, TeloView Test to Predict Patient Resistance to Treatment, development in collaboration with the Mayo Clinic and TeloView Test to monitor minimal residual disease in MM patients. The Company, by combining quantitative analysis of three-dimensional telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, is developing products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers.


TSXV:TELO - Post by User

Telo Genomics Corp > Webinar $TELO CEO Kris Weinberg Nov 21st @ 1PM ET / 10AM PT
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(35)
•••
Post by bmreedon Nov 17, 2023 5:29pm
189 Views
Post# 35742011

Webinar $TELO CEO Kris Weinberg Nov 21st @ 1PM ET / 10AM PT

Webinar $TELO CEO Kris Weinberg Nov 21st @ 1PM ET / 10AM PT

Live Webinar - Telo Genomics Corp $TELO w/ CEO Kris Weinberg

Tuesday, November 21st at 1PM ET / 10AM PT

Q&A with Radius Research 

Register Here - https://us02web.zoom.us/webinar/register/4017001560718/WN_kYeDpBRLRu6wQv1WPfdMHQ

 

CEO Kris Weinberg will provide a company overview and outline the 2024 commercialization plans along with upcoming catalysts.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities